Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial

Show other versions (2)

Bibliographic Details
Main Authors:	Hanke, T, Borthwick, N, Ahmed, T, Hayton, E, Ebrahimsa, U, Rose, A, Black, A, Yang, H, Hancock, G, Colloca, S, Nicosia, A, Mcmichael, A, Dorrell, L
Format:	Conference item
Published:	2012

Similar Items

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick, N, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick NJ, et al.
Published: (2012-09-01)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed, T, et al.
Published: (2012)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed T, et al.
Published: (2012-09-01)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
by: Ondondo, B, et al.
Published: (2013)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
by: Ondondo, B, et al.
Published: (2013)

IL-10 Receptor Blockade Enhances CD4 and CD8 T Cell Responses to a Simian Adenovirus-Vectored HIV-1 Vaccine, ChAdV63.HIVconsv
by: Clutton, G, et al.
Published: (2013)

Characterisation of T cells induced by candidate prophylactic vaccines encoding a HIV-1 conserved immunogen in phase I/IIa trial HIVCORE002
by: Ahmed, T, et al.
Published: (2011)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
by: Bliss, C, et al.
Published: (2016)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
by: Sheehy, S, et al.
Published: (2012)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
by: De Barra, E, et al.
Published: (2014)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
by: Kimani, D, et al.
Published: (2014)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
by: Mensah, V, et al.
Published: (2016)

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial
by: de Graaf, H, et al.
Published: (2021)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
by: Sheehy, S, et al.
Published: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
by: Sheehy, S, et al.
Published: (2011)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
by: Hans de Graaf, et al.
Published: (2021-07-01)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
by: Capone, S, et al.
Published: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
by: Capone, S, et al.
Published: (2010)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
by: Eoghan de Barra, et al.
Published: (2014-01-01)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
by: Victorine A Mensah, et al.
Published: (2016-01-01)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
by: Ogwang, C, et al.
Published: (2013)

Targeting HIV-1 Where It Hurts
by: Ahmed, T, et al.
Published: (2013)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
by: Borthwick, N, et al.
Published: (2013)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
by: Caroline Ogwang, et al.
Published: (2013-01-01)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
by: Hancock, G, et al.
Published: (2017)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
by: Borthwick, N, et al.
Published: (2014)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
by: Howles, S, et al.
Published: (2010)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
by: Borthwick, N, et al.
Published: (2014)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
by: Hodgson, S, et al.
Published: (2014)

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans
by: Sheehy, S, et al.
Published: (2012)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
by: Dorrell, L, et al.
Published: (2007)

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
by: Ondondo, B, et al.
Published: (2013)

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
by: Green, C, et al.
Published: (2015)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
by: Moyo, N, et al.
Published: (2017)

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
by: Sheehy, S, et al.
Published: (2012)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
by: Elias, S, et al.
Published: (2014)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
by: Ashley C. Beavis, et al.
Published: (2023-07-01)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
by: Tiono, AB, et al.
Published: (2018)

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS.
by: Hanke, T, et al.
Published: (1999)